Current Location:School > Home > Deparment of Pharmacy Administration and Clinical Pharmacy

Shao Hong


Associate Professor

Research Areas

Pharmacogenetics and Individualized Medication

Education and Practice System of Clinical Pharmacy

Education & Positions

Sichuan University (SU), B.S., 1981

Peking University Health Science Center (PUHSC), M.S., 1985

Peking University Health Science Center (PUHSC), Ph.D., 1991

Peking University Health Science Center (PUHSC), Assistant Professor, 1991-1997

Peking University Health Science Center (PUHSC), Associate Professor, 1997-

University of Kentucky, Visiting Scholar, 2007

Harvard Medical School / Boston Children’s Hospital, Visiting Associate Researcher, 2016-2017

Faculty Accolades

Excellent Mentor for Graduate Students, Peking University Health Science Center 2010-2011

Excellent Teacher in Educational Management, Peking UniversityHealth Science Center 2011

Award of Teaching Achievements, Peking University Health Science Center 2008


Research Interests

Pharmacogenetics (Pharmacogenomics) may greatly improve the level of clinical medication, enhance the outcomes of clinical medication, increase the efficiency of diagnosis and therapeutics, and maintain and promote the quality of patients’ life in the true sense. Its research results can provide guideline for target drugs in new drug screening, and directly contribute theoretic basis and therapeutically practical policy on clinical rational medication, individualized medication and precision medicine. The individualized medication regimens based on our pharmacogenetic studies in past twenty years involve renal transplantation, epilepsy, depression, hypertensive and cardiovascular diseases, diabetes, cancers (breast cancer, ALL, NHL), myasthenia gravis and immunosuppressive therapies, peptic ulcer and chronic gastritis, antibiotic and antibacterial therapies, fracture surgical treatment, etc.


Grants and fundings

Genetics of nicotine addiction vulnerability (NIH). Co-PI

The relationship between genetic polymorphisms and drug metabolism phenotypes (Ministry of Science and Technology – Peking University Innovative Drug Platform). Participator

Clinical study on ethaselen – first class targeting new antitumor drug (Ministry of Science and Technology). PI



Zhou X, Wang X, Song Q, Yang H, Zhu X, Yu J, Song G, Di L, Ren J, Shao H*, Lyerly HK. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy. International Journal of Clinical Pharmacology and Therapeutics 2015; 53:914-922

Zhang YT, Yang LP, Shao H*, Li KX, Sun CH, Shi LW. ABCB1 polymorphisms may have minor effect on ciclosporin blood concentration in myasthenia gravis patients. British Journal of Clinical Pharmacology 2008; 66(2):240-246

Ryan M, Shao H*, Yang L, Nie XY, Zhai SD, Shi LW, Lubawy WC. Clinical pharmacy education in China. American Journal of Pharmaceutical Education 2008; 72(6):A129

Shao H, Song SJ and Clarke RC. Female-associated DNA polymorphisms of hemp (Cannabis sativa L.). Journal of Industrial Hemp. 8(1):5-9. 2003

Niu TH, Chen CZ, Ni JT, Wang BY, Fang Z, Shao H*, Xu XP. Nicotine dependence and its familial aggregation in Chinese. International Journal of Epidemiology 2000; 29:248-252